Aflibercept is recommended, within its marketing authorisation, as an option for treating visual impairment because of myopic choroidal neovascularisation in adults, only if the company provides aflibercept with the discount agreed in the patient access scheme.
If patients and their clinicians consider both aflibercept and ranibizumab to be suitable treatments, the least costly should be used, taking into account anticipated administration costs, dosage and price per dose.
Ranibizumab is already recommended by NICE for treating choroidal neovascularisation. An indirect comparison of aflibercept and ranibizumab shows that both drugs provide similar overall health benefits. The total costs of aflibercept are the same as or less than those of ranibizumab.
Because it is has similar costs and overall health benefits to ranibizumab, aflibercept is also recommended as a cost-effective option for treating choroidal neovascularisation.